Description
Sutekast 50 mg contains Sunitinib Malate, a multi-targeted receptor tyrosine kinase (RTK) inhibitor. It blocks multiple pathways including VEGFR (vascular endothelial growth factor receptor) and PDGFR (platelet-derived growth factor receptor), which are responsible for tumor cell growth and angiogenesis.
By targeting these signaling pathways, Sunitinib helps slow tumor progression and limit the tumor’s blood supply.
🔬 Mechanism of Action
Sunitinib inhibits multiple tyrosine kinases involved in tumor proliferation, angiogenesis, and metastatic progression. This dual anti-tumor and anti-angiogenic activity makes it effective in treating advanced cancers.
💊 Indications
Sutekast 50 mg is indicated for:
- Advanced Renal Cell Carcinoma (RCC)
- Gastrointestinal Stromal Tumor (GIST) after failure or intolerance to imatinib
- Unresectable or metastatic Pancreatic Neuroendocrine Tumors (pNET)
📌 Key Features of Sutekast 50 mg
- Strength: 50 mg
- Dosage Form: Oral capsule
- Therapeutic Class: Multi-targeted Tyrosine Kinase Inhibitor
- Typical Regimen: Commonly administered in cycles (e.g., 4 weeks on treatment followed by 2 weeks off), as directed by an oncologist
- Monitoring: Regular blood pressure, thyroid function, liver function, and complete blood counts required
⚕️ Benefits of Sunitinib Malate
- Targeted cancer therapy
- Oral administration for patient convenience
- Helps delay disease progression
- Reduces tumor vascularization
⚠️ Precautions
- May cause hypertension, fatigue, hand-foot syndrome, mucositis, and gastrointestinal disturbances
- Cardiac monitoring may be required in certain patients
- Dose adjustments may be necessary based on tolerance and response
- Use strictly under oncologist supervision
Sutekast 50 mg (Sunitinib Malate Capsules) provides an advanced targeted treatment option for specific solid tumors, supporting improved disease control and patient outcomes when administered under expert medical care.
